Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer.

Vokes NI, Liu D, Ricciuti B, Jimenez-Aguilar E, Rizvi H, Dietlein F, He MX, Margolis CA, Elmarakeby HA, Girshman J, Adeni A, Sanchez-Vega F, Schultz N, Dahlberg S, Zehir A, Jänne PA, Nishino M, Umeton R, Sholl LM, Van Allen EM, Hellmann MD, Awad MM.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00171. Epub 2019 Nov 12.

2.

Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer.

Shaverdian N, Offin MD, Rimner A, Shepherd AF, Wu AJ, Rudin CM, Hellmann MD, Chaft JE, Gomez DR.

Radiother Oncol. 2019 Nov 28;144:101-104. doi: 10.1016/j.radonc.2019.11.015. [Epub ahead of print]

PMID:
31786421
3.

Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer.

Zhang J, Ji Z, Caushi JX, El Asmar M, Anagnostou V, Cottrell TR, Chan HY, Suri P, Guo H, Merghoub T, Chaft JE, Reuss JE, Tam AJ, Blosser RL, Abu-Akeel M, Sidhom JW, Zhao N, Ha JS, Jones DR, Marrone KA, Naidoo J, Gabrielson E, Taube JM, Velculescu VE, Brahmer JR, Housseau F, Hellmann MD, Forde PM, Pardoll DM, Ji H, Smith KN.

Clin Cancer Res. 2019 Nov 21. doi: 10.1158/1078-0432.CCR-19-2931. [Epub ahead of print]

PMID:
31754049
4.

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.

Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ, Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez-Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA.

Cancer Discov. 2020 Jan;10(1):40-53. doi: 10.1158/2159-8290.CD-19-0980. Epub 2019 Nov 15.

PMID:
31732494
5.

Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade.

Osorio JC, Arbour KC, Le DT, Durham JN, Plodkowski AJ, Halpenny DF, Ginsberg MS, Sawan P, Crompton JG, Yu HA, Namakydoust A, Nabet BY, Chaft JE, Riely GJ, Rizvi H, Diaz LA Jr, Hellmann MD.

J Clin Oncol. 2019 Dec 20;37(36):3546-3555. doi: 10.1200/JCO.19.00709. Epub 2019 Nov 1.

PMID:
31675272
6.

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort.

Ready NE, Ott PA, Hellmann MD, Zugazagoitia J, Hann CL, de Braud F, Antonia SJ, Ascierto PA, Moreno V, Atmaca A, Salvagni S, Taylor M, Amin A, Camidge DR, Horn L, Calvo E, Li A, Lin WH, Callahan MK, Spigel DR.

J Thorac Oncol. 2019 Oct 17. pii: S1556-0864(19)33531-2. doi: 10.1016/j.jtho.2019.10.004. [Epub ahead of print]

7.

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS.

N Engl J Med. 2019 Nov 21;381(21):2020-2031. doi: 10.1056/NEJMoa1910231. Epub 2019 Sep 28.

PMID:
31562796
8.

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.

Aguilar EJ, Ricciuti B, Gainor JF, Kehl KL, Kravets S, Dahlberg S, Nishino M, Sholl LM, Adeni A, Subegdjo S, Khosrowjerdi S, Peterson RM, Digumarthy S, Liu C, Sauter J, Rizvi H, Arbour KC, Carter BW, Heymach JV, Altan M, Hellmann MD, Awad MM.

Ann Oncol. 2019 Oct 1;30(10):1653-1659. doi: 10.1093/annonc/mdz288.

PMID:
31435660
9.

Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade.

Benci JL, Johnson LR, Choa R, Xu Y, Qiu J, Zhou Z, Xu B, Ye D, Nathanson KL, June CH, Wherry EJ, Zhang NR, Ishwaran H, Hellmann MD, Wolchok JD, Kambayashi T, Minn AJ.

Cell. 2019 Aug 8;178(4):933-948.e14. doi: 10.1016/j.cell.2019.07.019.

PMID:
31398344
10.

Use of Circulating Tumor DNA for Cancer Immunotherapy.

Snyder A, Morrissey MP, Hellmann MD.

Clin Cancer Res. 2019 Dec 1;25(23):6909-6915. doi: 10.1158/1078-0432.CCR-18-2688. Epub 2019 Jul 8. Review.

PMID:
31285372
11.

Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC.

Antonia SJ, Balmanoukian A, Brahmer J, Ou SI, Hellmann MD, Kim SW, Ahn MJ, Kim DW, Gutierrez M, Liu SV, Schöffski P, Jäger D, Jamal R, Jerusalem G, Lutzky J, Nemunaitis J, Calabrò L, Weiss J, Gadgeel S, Bhosle J, Ascierto PA, Rebelatto MC, Narwal R, Liang M, Xiao F, Antal J, Abdullah S, Angra N, Gupta AK, Khleif SN, Segal NH.

J Thorac Oncol. 2019 Oct;14(10):1794-1806. doi: 10.1016/j.jtho.2019.06.010. Epub 2019 Jun 20.

12.

Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.

Offin M, Chan JM, Tenet M, Rizvi HA, Shen R, Riely GJ, Rekhtman N, Daneshbod Y, Quintanal-Villalonga A, Penson A, Hellmann MD, Arcila ME, Ladanyi M, Pe'er D, Kris MG, Rudin CM, Yu HA.

J Thorac Oncol. 2019 Oct;14(10):1784-1793. doi: 10.1016/j.jtho.2019.06.002. Epub 2019 Jun 19.

PMID:
31228622
13.

Treatment Outcomes of Immune-Related Cutaneous Adverse Events.

Phillips GS, Wu J, Hellmann MD, Postow MA, Rizvi NA, Freites-Martinez A, Chan D, Dusza S, Motzer RJ, Rosenberg JE, Callahan MK, Chapman PB, Geskin L, Lopez AT, Reed VA, Fabbrocini G, Annunziata MC, Kukoyi O, Pabani A, Yang CH, Chung WH, Markova A, Lacouture ME.

J Clin Oncol. 2019 Oct 20;37(30):2746-2758. doi: 10.1200/JCO.18.02141. Epub 2019 Jun 19.

PMID:
31216228
14.

TOX is a critical regulator of tumour-specific T cell differentiation.

Scott AC, Dündar F, Zumbo P, Chandran SS, Klebanoff CA, Shakiba M, Trivedi P, Menocal L, Appleby H, Camara S, Zamarin D, Walther T, Snyder A, Femia MR, Comen EA, Wen HY, Hellmann MD, Anandasabapathy N, Liu Y, Altorki NK, Lauer P, Levy O, Glickman MS, Kaye J, Betel D, Philip M, Schietinger A.

Nature. 2019 Jul;571(7764):270-274. doi: 10.1038/s41586-019-1324-y. Epub 2019 Jun 17.

PMID:
31207604
15.

Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers.

Offin M, Guo R, Wu SL, Sabari J, Land JD, Ni A, Montecalvo J, Halpenny DF, Buie LW, Pak T, Liu D, Riely GJ, Hellmann MD, Benayed R, Arcila M, Kris MG, Rudin CM, Li BT, Ladanyi M, Rekhtman N, Drilon A.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00386. Epub 2019 May 16. No abstract available.

16.

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.

Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Felip E, Goldman JW, Scalzo C, Jensen E, Kush DA, Hui R.

J Clin Oncol. 2019 Oct 1;37(28):2518-2527. doi: 10.1200/JCO.19.00934. Epub 2019 Jun 2.

17.

Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer.

Hu-Lieskovan S, Lisberg A, Zaretsky JM, Grogan TR, Rizvi H, Wells DK, Carroll J, Cummings A, Madrigal J, Jones B, Gukasyan J, Shintaku IP, Slamon D, Dubinett S, Goldman JW, Elashoff D, Hellmann MD, Ribas A, Garon EB.

Clin Cancer Res. 2019 Aug 15;25(16):5061-5068. doi: 10.1158/1078-0432.CCR-18-4275. Epub 2019 May 21.

18.

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.

Hastings K, Yu HA, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, Liu Z, Henick BS, Wurtz A, Cai G, Plodkowski AJ, Long NM, Halpenny DF, Killam J, Oliva I, Schultz N, Riely GJ, Arcila ME, Ladanyi M, Zelterman D, Herbst RS, Goldberg SB, Awad MM, Garon EB, Gettinger S, Hellmann MD, Politi K.

Ann Oncol. 2019 Aug 1;30(8):1311-1320. doi: 10.1093/annonc/mdz141.

19.

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.

Datar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, Dong W, Mani N, Toki M, Mejías LD, Lozano MD, Perez-Gracia JL, Velcheti V, Hellmann MD, Gainor JF, McEachern K, Jenkins D, Syrigos K, Politi K, Gettinger S, Rimm DL, Herbst RS, Melero I, Chen L, Schalper KA.

Clin Cancer Res. 2019 Aug 1;25(15):4663-4673. doi: 10.1158/1078-0432.CCR-18-4142. Epub 2019 May 3.

PMID:
31053602
20.

Rational design of anti-GITR-based combination immunotherapy.

Zappasodi R, Sirard C, Li Y, Budhu S, Abu-Akeel M, Liu C, Yang X, Zhong H, Newman W, Qi J, Wong P, Schaer D, Koon H, Velcheti V, Hellmann MD, Postow MA, Callahan MK, Wolchok JD, Merghoub T.

Nat Med. 2019 May;25(5):759-766. doi: 10.1038/s41591-019-0420-8. Epub 2019 Apr 29.

PMID:
31036879
21.

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.

Hellmann MD, Kim TW, Lee CB, Goh BC, Miller WH, Oh DY, Jamal R, Chee CE, Chow LQM, Gainor JF, Desai J, Solomon BJ, Das Thakur M, Pitcher B, Foster P, Hernandez G, Wongchenko MJ, Cha E, Bang YJ, Siu LL, Bendell J.

Ann Oncol. 2019 Jul 1;30(7):1134-1142. doi: 10.1093/annonc/mdz113.

PMID:
30918950
22.

How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer.

Peters S, Reck M, Smit EF, Mok T, Hellmann MD.

Ann Oncol. 2019 Jun 1;30(6):884-896. doi: 10.1093/annonc/mdz109.

PMID:
30912805
23.

Neoantigen-directed immune escape in lung cancer evolution.

Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, Lund T, Tanić M, Reading JL, Joshi K, Henry JY, Ghorani E, Wilson GA, Birkbak NJ, Jamal-Hanjani M, Veeriah S, Szallasi Z, Loi S, Hellmann MD, Feber A, Chain B, Herrero J, Quezada SA, Demeulemeester J, Van Loo P, Beck S, McGranahan N, Swanton C; TRACERx consortium.

Nature. 2019 Mar;567(7749):479-485. doi: 10.1038/s41586-019-1032-7. Epub 2019 Mar 20.

24.

Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.

Leighl NB, Hellmann MD, Hui R, Carcereny E, Felip E, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Lubiniecki GM, Zhang J, Piperdi B, Garon EB.

Lancet Respir Med. 2019 Apr;7(4):347-357. doi: 10.1016/S2213-2600(18)30500-9. Epub 2019 Mar 12.

PMID:
30876831
25.

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib.

Schoenfeld AJ, Arbour KC, Rizvi H, Iqbal AN, Gadgeel SM, Girshman J, Kris MG, Riely GJ, Yu HA, Hellmann MD.

Ann Oncol. 2019 May 1;30(5):839-844. doi: 10.1093/annonc/mdz077.

PMID:
30847464
26.

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.

Ready N, Hellmann MD, Awad MM, Otterson GA, Gutierrez M, Gainor JF, Borghaei H, Jolivet J, Horn L, Mates M, Brahmer J, Rabinowitz I, Reddy PS, Chesney J, Orcutt J, Spigel DR, Reck M, O'Byrne KJ, Paz-Ares L, Hu W, Zerba K, Li X, Lestini B, Geese WJ, Szustakowski JD, Green G, Chang H, Ramalingam SS.

J Clin Oncol. 2019 Apr 20;37(12):992-1000. doi: 10.1200/JCO.18.01042. Epub 2019 Feb 20.

PMID:
30785829
27.

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.

Jung KH, LoRusso P, Burris H, Gordon M, Bang YJ, Hellmann MD, Cervantes A, de Olza MO, Marabelle A, Hodi FS, Ahn MJ, Emens LA, Barlesi F, Hamid O, Calvo E, McDermott D, Soliman H, Rhee I, Lin R, Pourmohamad T, Suchomel J, Tsuhako A, Morrissey K, Mahrus S, Morley R, Pirzkall A, Davis SL.

Clin Cancer Res. 2019 Jun 1;25(11):3220-3228. doi: 10.1158/1078-0432.CCR-18-2740. Epub 2019 Feb 15.

PMID:
30770348
28.

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, Rizvi NA, Hirsch FR, Selvaggi G, Szustakowski JD, Sasson A, Golhar R, Vitazka P, Chang H, Geese WJ, Antonia SJ.

Cancer Cell. 2019 Feb 11;35(2):329. doi: 10.1016/j.ccell.2019.01.011. No abstract available.

PMID:
30753829
29.

Adding to the checkpoint blockade armamentarium.

Hellmann MD, Snyder A.

Nat Med. 2019 Feb;25(2):203-205. doi: 10.1038/s41591-019-0350-5. No abstract available.

PMID:
30728540
30.

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S.

Ann Oncol. 2019 May 1;30(5):863-870. doi: 10.1093/annonc/mdy474. No abstract available.

PMID:
30715168
31.

Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D'Angelo SP, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT.

Nat Genet. 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8. Epub 2019 Jan 14.

PMID:
30643254
32.

Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

Anagnostou V, Forde PM, White JR, Niknafs N, Hruban C, Naidoo J, Marrone K, Sivakumar IKA, Bruhm DC, Rosner S, Phallen J, Leal A, Adleff V, Smith KN, Cottrell TR, Rhymee L, Palsgrove DN, Hann CL, Levy B, Feliciano J, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Isbell JM, Sauter JL, Taube J, Scharpf RB, Karchin R, Pardoll DM, Chaft JE, Hellmann MD, Brahmer JR, Velculescu VE.

Cancer Res. 2019 Mar 15;79(6):1214-1225. doi: 10.1158/0008-5472.CAN-18-1127. Epub 2018 Dec 12.

33.

Clinical Characterization of Immunotherapy-Related Pruritus Among Patients Seen in 2 Oncodermatology Clinics.

Phillips GS, Freites-Martinez A, Wu J, Chan D, Fabbrocini G, Hellmann MD, Lacouture ME.

JAMA Dermatol. 2019 Feb 1;155(2):249-251. doi: 10.1001/jamadermatol.2018.4560. No abstract available.

34.

A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers.

Sabari JK, Offin M, Stephens D, Ni A, Lee A, Pavlakis N, Clarke S, Diakos CI, Datta S, Tandon N, Martinez A, Myers ML, Makhnin A, Leger Y, Yu HA, Paik PK, Chaft JE, Kris MG, Jeon JO, Borsu LA, Ladanyi M, Arcila ME, Hernandez J, Henderson S, Shaffer T, Garg K, DiPasquo D, Raymond CK, Lim LP, Li M, Hellmann MD, Drilon A, Riely GJ, Rusch VW, Jones DR, Rimner A, Rudin CM, Isbell JM, Li BT.

J Natl Cancer Inst. 2018 Nov 28. doi: 10.1093/jnci/djy156. [Epub ahead of print]

35.

Acquired resistance to immunotherapy in MMR-D pancreatic cancer.

Hu ZI, Hellmann MD, Wolchok JD, Vyas M, Shia J, Stadler ZK, Diaz LA Jr, O'Reilly EM.

J Immunother Cancer. 2018 Nov 20;6(1):127. doi: 10.1186/s40425-018-0448-1.

36.

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection.

Tio M, Rai R, Ezeoke OM, McQuade JL, Zimmer L, Khoo C, Park JJ, Spain L, Turajlic S, Ardolino L, Yip D, Goldinger SM, Cohen JV, Millward M, Atkinson V, Kane AY, Ascierto PA, Garbe C, Gutzmer R, Johnson DB, Rizvi HA, Joshua AM, Hellmann MD, Long GV, Menzies AM.

Eur J Cancer. 2018 Nov;104:137-144. doi: 10.1016/j.ejca.2018.09.017. Epub 2018 Oct 20.

PMID:
30347289
37.

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032.

Ready N, Farago AF, de Braud F, Atmaca A, Hellmann MD, Schneider JG, Spigel DR, Moreno V, Chau I, Hann CL, Eder JP, Steele NL, Pieters A, Fairchild J, Antonia SJ.

J Thorac Oncol. 2019 Feb;14(2):237-244. doi: 10.1016/j.jtho.2018.10.003. Epub 2018 Oct 10.

38.

Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.

Zappasodi R, Budhu S, Hellmann MD, Postow MA, Senbabaoglu Y, Manne S, Gasmi B, Liu C, Zhong H, Li Y, Huang AC, Hirschhorn-Cymerman D, Panageas KS, Wherry EJ, Merghoub T, Wolchok JD.

Cancer Cell. 2018 Oct 8;34(4):691. doi: 10.1016/j.ccell.2018.09.007. No abstract available.

39.

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237. doi: 10.1093/annonc/mdy275. No abstract available. Erratum in: Ann Oncol. 2019 May 1;30(5):863-870.

40.

Lung Cancer with a High Tumor Mutational Burden.

Hellmann MD, Paz-Ares L.

N Engl J Med. 2018 Sep 13;379(11):1093-1094. doi: 10.1056/NEJMc1808566. No abstract available.

PMID:
30207915
41.

Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition.

von Reibnitz D, Chaft JE, Wu AJ, Samstein R, Hellmann MD, Plodkowski AJ, Zhang Z, Shi W, Dick-Godfrey R, Panchoo KH, Barker CA, Rimner A.

Adv Radiat Oncol. 2018 May 9;3(3):391-398. doi: 10.1016/j.adro.2018.05.001. eCollection 2018 Jul-Sep.

42.

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.

Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, Chen R, Dienstag J, Mrad C, Bergagnini I, Lai WV, Offin M, Arbour KC, Plodkowski AJ, Halpenny DF, Paik PK, Li BT, Riely GJ, Kris MG, Rudin CM, Sholl LM, Nishino M, Hellmann MD, Rekhtman N, Awad MM, Drilon A.

Ann Oncol. 2018 Oct 1;29(10):2085-2091. doi: 10.1093/annonc/mdy334.

43.

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.

Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, Martínez-Bernal G, Ferrara R, Lai WV, Hendriks LEL, Sabari JK, Caramella C, Plodkowski AJ, Halpenny D, Chaft JE, Planchard D, Riely GJ, Besse B, Hellmann MD.

J Clin Oncol. 2018 Oct 1;36(28):2872-2878. doi: 10.1200/JCO.2018.79.0006. Epub 2018 Aug 20.

PMID:
30125216
44.

Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.

Offin M, Rizvi H, Tenet M, Ni A, Sanchez-Vega F, Li BT, Drilon A, Kris MG, Rudin CM, Schultz N, Arcila ME, Ladanyi M, Riely GJ, Yu H, Hellmann MD.

Clin Cancer Res. 2019 Feb 1;25(3):1063-1069. doi: 10.1158/1078-0432.CCR-18-1102. Epub 2018 Jul 25.

PMID:
30045933
45.

Multiple Resolution Residually Connected Feature Streams for Automatic Lung Tumor Segmentation From CT Images.

Jiang J, Hu YC, Liu CJ, Halpenny D, Hellmann MD, Deasy JO, Mageras G, Veeraraghavan H.

IEEE Trans Med Imaging. 2019 Jan;38(1):134-144. doi: 10.1109/TMI.2018.2857800. Epub 2018 Jul 23.

46.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).

Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, Hellmann MD, Hirsch FR, Malik S, Neal JW, Papadimitrakopoulou VA, Rimm DL, Schwartz LH, Sepesi B, Yeap BY, Rizvi NA, Herbst RS.

J Immunother Cancer. 2018 Jul 17;6(1):75. doi: 10.1186/s40425-018-0382-2.

47.

Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC.

Santini FC, Rizvi H, Plodkowski AJ, Ni A, Lacouture ME, Gambarin-Gelwan M, Wilkins O, Panora E, Halpenny DF, Long NM, Kris MG, Rudin CM, Chaft JE, Hellmann MD.

Cancer Immunol Res. 2018 Sep;6(9):1093-1099. doi: 10.1158/2326-6066.CIR-17-0755. Epub 2018 Jul 10.

48.

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).

Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, Rekhtman N, Anders RA, Cuda JD, Illei PB, Gabrielson E, Askin FB, Niknafs N, Smith KN, Velez MJ, Sauter JL, Isbell JM, Jones DR, Battafarano RJ, Yang SC, Danilova L, Wolchok JD, Topalian SL, Velculescu VE, Pardoll DM, Brahmer JR, Hellmann MD, Chaft JE, Cimino-Mathews A, Taube JM.

Ann Oncol. 2018 Aug 1;29(8):1853-1860. doi: 10.1093/annonc/mdy218.

49.

30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT).

de Marinis F, Ciardiello F, Baas P, Crinò L, Giaccone G, Grossi F, Hellmann MD, Mok TSK, Lena H, Paz-Ares L, Rodriguez-Abreu D, Von Pavel J, Gridelli C.

ESMO Open. 2018 May 31;3(4):e000298. doi: 10.1136/esmoopen-2017-000298. eCollection 2018. Review.

50.

Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.

Zappasodi R, Budhu S, Hellmann MD, Postow MA, Senbabaoglu Y, Manne S, Gasmi B, Liu C, Zhong H, Li Y, Huang AC, Hirschhorn-Cymerman D, Panageas KS, Wherry EJ, Merghoub T, Wolchok JD.

Cancer Cell. 2018 Jun 11;33(6):1017-1032.e7. doi: 10.1016/j.ccell.2018.05.009. Erratum in: Cancer Cell. 2018 Oct 8;34(4):691.

Supplemental Content

Loading ...
Support Center